Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Onset of Labor and Metabolomics (GEM-2) (GEM-2)

11. maj 2015 opdateret af: Jean-Charles Pasquier, MD, PhD, Université de Sherbrooke

Feasibility Study to Develop the Analysis of the Metabolome During the Onset of Labor During Pregnancy

Premature birth is a public health problem and its incidence has recently increased in all developed countries. In Canada, it represented 6.4% of births in 1981 and 7.6% in 2000. In the last decade, the survival rate of premature infants has increased considerably, but neurological vulnerability has not changed. Premature births are the cause of approximately 28% of neonatal mortality in the world and is the major cause of perinatal mortality and morbidity in developed countries.

Approximately 75-80% of preterm births are spontaneous preterm birth. This type of premature birth included the preterm labor and premature rupture of membranes before term. The contractile activity represents one of the fundamental properties of the uterus during pregnancy and childbirth. The abnormalities associated with uterine contractions are the cause of pathological conditions with important consequences for the mother and fetus.

Metabolomics involves a new technology to investigate small molecules that characterize biochemical pathways of interest. The change in concentration levels of these molecules in various biological samples such as urine and blood in the presence of a disease or a patient can be particularly useful for identifying new biomarkers.

The hypothesis of this study is that gestational metabolomes detected in maternal fluids differ according to pathological situations and lead to the initiation of spontaneous labor. The whole research program has two complementary objectives in order to expect a decrease of prematurity: a) better understanding of all the physiological mechanisms leading to prematurity and b) better identification of patients at high risk for a better management of these women.

Studieoversigt

Status

Ukendt

Betingelser

Detaljeret beskrivelse

Metabolomics involves a new technology using the methods of separation and detection complex to investigate a set of small molecules that characterize biochemical pathways of interest. The change in concentration levels of these molecules in various biological samples such as urine and blood in the presence of a disease or a patient can detect metabolic fingerprints that can be particularly useful for identifying new biomarkers. These will thereafter be quantified and validated by metabolic profiling. To our knowledge, there are few studies on metabolomics and pregnancy.

Methods:

The studied population will be pregnant women between 20-30 weeks of gestation without any obstetrical complications.

Vaginal secretions, blood and urine samples will be taken:

  • After inclusion in the project
  • At hospital admission for delivery
  • During labor

Blood and urine sample will also be taken:

  • 48 hours after delivery
  • 6-8 weeks after delivery

Undersøgelsestype

Observationel

Tilmelding (Forventet)

80

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Centre Hospitalier de l'Université de Sherbrooke

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Pregnant women between 20-30 weeks of gestation who have a low risk pregnancy.

Beskrivelse

Inclusion Criteria:

  • Women with single pregnancy
  • Adults (> 18 years old)

Exclusion Criteria:

  • Women with a severe congenital fetal malformation
  • Fetal death
  • Preexisting hypertension (ie before 20 weeks of gestation)
  • Anti-phospholipid syndrome
  • Lupus,
  • Nephropathy, etc.
  • Viral infections (HIV or hepatitis)
  • Women who want an elective Caesarean section are excluded

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
GEM-2 Cohort
Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
comparison between the metabolic patterns of women before and during labor
Tidsramme: one and half year
one and half year

Sekundære resultatmål

Resultatmål
Tidsramme
The study also looks at the comparison of metabolic patterns in late pregnancy and postpartum.
Tidsramme: one and half year
one and half year
The project will characterize the metabolome in different fluids collected
Tidsramme: one and half year
one and half year
The study will compare the metabolome of women with spontaneous onset of labor with that of women with premature rupture of membranes or induction of labor
Tidsramme: one and half year
one and half year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. april 2009

Primær færdiggørelse (Forventet)

1. marts 2017

Studieafslutning (Forventet)

1. juni 2017

Datoer for studieregistrering

Først indsendt

18. februar 2010

Først indsendt, der opfyldte QC-kriterier

18. februar 2010

Først opslået (Skøn)

19. februar 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

12. maj 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. maj 2015

Sidst verificeret

1. maj 2015

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 09-041

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Graviditet

  • King's College Hospital NHS Trust
    European Association for the Study of the Liver
    Rekruttering
    Cirrhose, lever | HELLP syndrom | Intrahepatisk kolestase af graviditet | Graviditetssygdom | AFLP - Acute Fatty Lever of Pregnancy
    Det Forenede Kongerige
Abonner